Vertex Pharmaceuticals (VRTX) stock
Last close $520.66 on 2026-11-19 (-2.94%) · Sector: Healthcare
Vertex Pharmaceuticals is a Boston-based biotech company that develops medicines for serious diseases, and it is best known for its treatments for cystic fibrosis. It makes most of its money by selling these prescription medicines to patients, hospitals, and pharmacies.
Vertex has a strong business, with gross margin around 85.5% and revenue growing 10.5% over the past year. Over the past year the stock returned 23.3%, beating the S&P 500's 9.7%, and it trades about 7.4% above its 200-day average. Insiders sold about $15.4M of stock over the last 90 days and made no purchases, and the stock has risen after only two of its four recent earnings reports.
Key numbers
- Market cap: $132.9B
- Revenue (last 12 months): $12.95B
- Revenue growth: +10.5%
- Gross margin: 85.5%
- Operating margin: 33.3%
- P/E: 33.5
- P/S: 10.3
- Debt to equity: 0.17
- Current ratio: 2.34
Quality score
Overall 45/100 · growth 38 · profitability 60 · financial health 72 · value 11
Performance and risk
1-year return +23.3% vs S&P 500 +9.7% · volatility 29.6% (S&P 500 13.8%) · largest drop -15.2% · beta 0.47
Stock move the day after earnings
- 2026-02-12: +5.7%
- 2026-05-04: -1.3%
- 2026-08-03: +1.7%
- 2026-11-02: -4.0%
Congress trades (90 days)
0 buys, 2 sells
Insider trades (12 months)
Bought $0.0M · sold $140.0M
VRTX stock research · VRTX options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.